Abliva AB
STO:ABLI

Watchlist Manager
Abliva AB Logo
Abliva AB
STO:ABLI
Watchlist
Price: 0.444 SEK 0.23% Market Closed
Market Cap: kr715.7m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
kr0
/
kr0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
kr0
/
kr0

Peer Comparison

Country Company Market Cap Operating
Margin
SE
Abliva AB
STO:ABLI
715.7m SEK
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
393.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
172.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Abliva AB
Glance View

Market Cap
715.7m SEK
Industry
Biotechnology

Abliva AB is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of primary mitochondrial diseases. The company is headquartered in Lund, Skane. The company went IPO on 2008-10-03. The firm focuses on the development of novel treatments for primary mitochondrial diseases.

ABLI Intrinsic Value
0.06 SEK
Overvaluation 87%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top